Magnetic heart scan may outshine ECG for predicting dangerous heart rhythms

NCT ID NCT07270211

Not yet recruiting Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study at Mayo Clinic will enroll 100 adults with atrial fibrillation who are taking the drug dofetilide. Researchers will compare a non-invasive magnetic heart scan (magnetocardiography, or MCG) with the standard ECG to see which better predicts safe drug dosing and heart complications. The goal is to improve safety and outcomes for people with Long QT syndrome.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If MCG proves more accurate than ECG, it could become a new standard for monitoring heart rhythm risks, helping doctors make safer treatment decisions.
What could go wrong: This is an early observational study with only 100 participants, so results may not apply to everyone. MCG is still experimental and not widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation long QT syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.